[go: up one dir, main page]

AR113224A1 - ANTIBODY CONJUGATES INCLUDING A STING AGONIST - Google Patents

ANTIBODY CONJUGATES INCLUDING A STING AGONIST

Info

Publication number
AR113224A1
AR113224A1 ARP180101063A ARP180101063A AR113224A1 AR 113224 A1 AR113224 A1 AR 113224A1 AR P180101063 A ARP180101063 A AR P180101063A AR P180101063 A ARP180101063 A AR P180101063A AR 113224 A1 AR113224 A1 AR 113224A1
Authority
AR
Argentina
Prior art keywords
antibody conjugates
sting agonist
conjugates including
immunoconjugates
methods
Prior art date
Application number
ARP180101063A
Other languages
Spanish (es)
Inventor
Yongqin Wan
Tom Yao Wu
- Uno Tetsuo Hsiang
George Scott Tria
Leonard Sung
Weijia Ou
Chudiobioma Ndubaku
Sarah Mwhirter
Jeffrey Mkenna
Justin Leong
Thanh Ngoc Lan Le
George Edwin Katibah
Shailaja Kasibhatla
David Kanne
Xueshi Hao
Laura Glickman
Kelsey Gauthier
Thomas W Dubensky
Charles Y Cho
Stephen Canham
Jacob Robert Bruml
Original Assignee
Novartis Ag
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Aduro Biotech Inc filed Critical Novartis Ag
Publication of AR113224A1 publication Critical patent/AR113224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente inmunoconjugados que comprenden agonistas de STING. También se dan a conocer métodos para producir los inmunoconjugados y métodos de tratamiento del cáncer usando los inmunoconjugados.Immunoconjugates comprising STING agonists are provided herein. Methods for producing the immunoconjugates and methods of treating cancer using the immunoconjugates are also disclosed.

ARP180101063A 2017-04-28 2018-04-25 ANTIBODY CONJUGATES INCLUDING A STING AGONIST AR113224A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762491879P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
AR113224A1 true AR113224A1 (en) 2020-02-19

Family

ID=62165655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101063A AR113224A1 (en) 2017-04-28 2018-04-25 ANTIBODY CONJUGATES INCLUDING A STING AGONIST

Country Status (5)

Country Link
EP (1) EP3615080A1 (en)
JP (1) JP2020517700A (en)
CN (1) CN110799218A (en)
AR (1) AR113224A1 (en)
WO (1) WO2018200812A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102847350B1 (en) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 Antibody-drug conjugate comprising a branched linker and method for preparing the same
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
JP7664680B2 (en) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． Pyrrolobenzodiazepine dimer precursors and their ligand-linker conjugate compounds
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds compositions, and methods for the treatment of disease
TW201922263A (en) 2017-11-10 2019-06-16 日商武田藥品工業股份有限公司 Modulator of interferon gene stimulating protein, and method of manufacture and use thereof
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
SG11202010443WA (en) 2018-05-09 2020-11-27 Legochem Biosciences Inc Compositions and methods related to anti-cd19 antibody drug conjugates
CN112512531B (en) * 2018-06-01 2024-04-09 卫材R&D管理有限公司 Methods for the treatment of bladder cancer
CA3106110A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020089815A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
CN113348181A (en) * 2018-10-31 2021-09-03 诺华股份有限公司 DC-SIGN antibody conjugates comprising a STING agonist
EP4406555A3 (en) * 2018-12-21 2024-11-06 Novartis AG Antibodies to pmel17 and conjugates thereof
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
JP7621974B2 (en) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Modified cyclic dinucleoside compounds as STING modulators
CN119770674A (en) 2019-05-10 2025-04-08 武田药品工业株式会社 Antibody Drug Conjugates
US20230081720A1 (en) 2019-05-20 2023-03-16 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3980423A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
WO2020248065A1 (en) * 2019-06-12 2020-12-17 Ontario Institute For Cancer Research (Oicr) Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof
CN117838878A (en) 2019-07-19 2024-04-09 免疫传感器治疗股份有限公司 Antibody-STING agonist conjugates and their use in immunotherapy
JP2022543086A (en) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド Bis-[N-((5-carbamoyl)-1H-benzo[d]imidazol-2-yl)-pyrazole-5-carboxamide] derivatives as STING (interferon gene stimulator) agonists for the treatment of cancer and related Compound
JP7414965B2 (en) * 2019-08-21 2024-01-16 ザ スクリプス リサーチ インスティテュート Bicyclic agonist of interferon gene stimulator STING
KR20210028544A (en) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
US20230074385A1 (en) * 2019-12-23 2023-03-09 Eisai R&D Management Co., Ltd. Method for producing eribulin-based antibody-drug conjugate
CA3168368A1 (en) * 2020-03-06 2021-09-10 Masayuki Ishizaki Antibody-drug conjugate including novel cyclic dinucleotide derivative
US20230338564A1 (en) * 2020-03-31 2023-10-26 Orum Therapeutics, Inc. Neodegrader conjugates
CN116196435B (en) * 2020-04-02 2025-12-02 梅尔莎纳医疗公司 Antibody drug conjugates containing STING agonists
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
CN111592570B (en) * 2020-05-15 2022-04-29 清华大学 Novel STING agonist and its preparation method and application
IL298148A (en) 2020-05-15 2023-01-01 Immunesensor Therapeutics Inc Sting agonist combination treatments with immune checkpoint inhibitors
IL302390A (en) * 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Antibody drug conjugates
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
JP2024514707A (en) 2021-04-20 2024-04-02 アンスティテュ・クリー Compositions and methods for use in immunotherapy
JP7742892B2 (en) 2021-04-23 2025-09-22 ジェンマブ エー／エス Anti-CD70 antibodies, conjugates thereof and methods of using same
TW202320857A (en) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 Linkers, drug linkers and conjugates thereof and methods of using the same
CN118284423A (en) 2021-07-23 2024-07-02 免疫传感器治疗股份有限公司 Combination therapy of STING agonists and cytokines
TW202342105A (en) * 2021-12-17 2023-11-01 大陸商北京加科思新藥研發有限公司 Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof
CN115060902B (en) * 2022-05-13 2025-07-11 上海市第十人民医院 cGAS methylation modification and its detection reagent and application as a marker for tumor diagnosis and prognosis analysis
EP4558511A2 (en) 2022-07-21 2025-05-28 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024100452A2 (en) * 2022-11-08 2024-05-16 Legochem Biosciences, Inc. Heterocyclic compounds as sting agonists
KR20250129814A (en) * 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 Antibody-drug conjugates and uses thereof
KR20250160354A (en) 2023-03-10 2025-11-12 노파르티스 아게 PANRAS inhibitor antibody-drug conjugates and methods of use thereof
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy
AR133955A1 (en) 2023-09-26 2025-11-19 Profoundbio Us Co PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USE THEREOF
WO2025140587A1 (en) * 2023-12-27 2025-07-03 上海迪诺医药科技有限公司 Cyclic dinucleotide compound, conjugate thereof, and use thereof
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025233676A1 (en) * 2024-05-08 2025-11-13 Ligachem Biosciences Inc. Compositions and methods related to a combination therapy of sting agonists and immune checkpoint inhibitors
WO2025233679A1 (en) * 2024-05-08 2025-11-13 Ligachem Biosciences Inc. Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839147T2 (en) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. ARTIFICIAL ANTIBODY POLYPEPTIDE
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN104524590B (en) 2008-04-30 2019-06-21 伊缪诺金公司 The purposes of crosslinking agent and they
IN2015DN02913A (en) 2012-11-30 2015-09-18 Novartis Ag
KR20150095668A (en) 2012-12-13 2015-08-21 아두로 바이오테크, 인코포레이티드 Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
MX2015010146A (en) * 2013-02-08 2016-05-31 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates.
JP2016524593A (en) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター Compositions and methods for altering second messenger signaling
US9724408B2 (en) 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
MX2016015928A (en) 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Cyclic di-nucleotides as modulators of sting.
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
JP6692826B2 (en) * 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． Compositions and methods for activation of "interferon gene stimulator" dependent signaling
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
HK1252343A1 (en) 2015-07-02 2019-05-24 春季银行制药股份有限公司 Compositions and methods for the treatment of viral infection
TW201717968A (en) 2015-07-14 2017-06-01 春季銀行製藥公司 Compounds and compositions that induce RIG-I and other pattern recognition receptors
WO2017019896A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
UA123701C2 (en) 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Cyclic di-nucleotide compounds as sting agonists
WO2017100305A2 (en) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof
CN106540256A (en) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 Ring dinucleotide-application of the liposome conjugated monoclonal antibodies in antitumor
TW201803886A (en) 2016-07-06 2018-02-01 史貝羅威生物科學有限公司 Compounds, compositions, and methods for the treatment of disease
WO2018009648A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
EP3484504A4 (en) 2016-07-15 2020-07-29 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease

Also Published As

Publication number Publication date
WO2018200812A1 (en) 2018-11-01
JP2020517700A (en) 2020-06-18
EP3615080A1 (en) 2020-03-04
CN110799218A (en) 2020-02-14

Similar Documents

Publication Publication Date Title
AR113224A1 (en) ANTIBODY CONJUGATES INCLUDING A STING AGONIST
MX2021007620A (en) Ror1 antibody immunoconjugates.
ECSP18038868A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
CY1124131T1 (en) ANTI-RTK7 ANTIBODY-DRUG CONJUGATS
CL2019003050A1 (en) Antibody conjugates comprising toll-like receptor agonists and combination therapies.
CL2018003758A1 (en) Anti-dll3-antibody antibody conjugates and methods of use. (divisional application 201800458)
UY38433A (en) DC – SIGN ANTIBODY CONJUGATES INCLUDING STING AGONISTS
CY1124230T1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
CL2018003406A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof.
MX2024006675A (en) Igf-1r monoclonal antibodies and uses thereof.
CO2018004152A2 (en) Antibody-pyrrolobenzodiazepine drug conjugates and methods of use
CO2017010618A2 (en) Antibodies against icos
MX2017003126A (en) Anti-her2 antibodies and immunoconjugates.
CO2018005433A2 (en) Site-specific her2 antibody drug conjugates
CL2025000404A1 (en) Anti-Lilrb1 antibody and its uses
CO2017004516A2 (en) Humanized anti-ox40 antibodies
MX2017003022A (en) Anti-cll-1 antibodies and immunoconjugates.
CL2019003168A1 (en) Pharmacokinetic improvements of bifunctional chelates and their uses.
CL2016002667A1 (en) Novel anti-rnf43 antibodies and methods for use
CL2018001722A1 (en) New anti-mfi2 antibodies and methods of use (divisional application 201700506)
MX2020007748A (en) METHODS FOR TREATING CANCERS WITH ANTI-PD-1 ANTAGONIST ANTIBODIES.
CR20150482A (en) ANTI-B7-H4 ANTIBODIES AND IMMUNOCATION
MX2019004690A (en) Antibody constructs.
MX2015015091A (en) COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE.
MX370829B (en) USE OF AN ANTIBODY FOR CD20 AFUCOSILATED WITH A CONJUGATE OF ANTIBODY FOR CD22-DRUG.

Legal Events

Date Code Title Description
FB Suspension of granting procedure